Christine Lovly, MD
Medical Oncology · Duarte, CANPI 1265589071
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $296,592 of the $362,489 with a category attached, or 81.8%. It is spread thinly across 35 manufacturers, the largest accounting for just 13.1%. 2025 is the largest year on record at $108,410, 3.1 times the $35,179 reported in 2019. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $1427.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$47K
- AstraZeneca$44K
- Pfizer$41K
- Daiichi Sankyo Inc.$36K
- E.r. Squibb & Sons, L.L.C.$25K
- Gilead$20K
- plus $149K from 29 others
Across 11 payments — averaging $88,045 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$762K
- Astrazeneca UK Limited$198K
- AstraZeneca$7K
- F. Hoffmann-la Roche AG$1K
What the payments were for
- Consulting fees$296,59282%
- Speaking & faculty fees$34,94810%
- Travel & lodging$21,6596%
- Food & beverage$9,2903%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $47,361 |
| AstraZeneca | 39 | $43,616 |
| Pfizer | 23 | $40,625 |
| Daiichi Sankyo Inc. | 18 | $36,474 |
| E.r. Squibb & Sons, L.L.C. | 13 | $25,346 |
| Gilead | 15 | $19,661 |
| Foundation Medicine, Inc. | 10 | $17,630 |
| Amgen | 7 | $15,536 |
| AbbVie | 11 | $11,694 |
| Eli Lilly | 13 | $10,618 |
| Boehringer Ingelheim International GmbH | 5 | $10,617 |
| Genentech USA, Inc. | 8 | $8,500 |
| Merck | 5 | $7,184 |
| Janssen Scientific Affairs, LLC | 6 | $7,168 |
| Jazz Pharmaceuticals Inc. | 1 | $6,592 |
| Cepheid | 3 | $6,000 |
| Genentech, Inc. | 4 | $5,913 |
| EMD Serono, Inc. | 2 | $5,673 |
| Johnson & Johnson | 3 | $5,258 |
| Blueprint Medicines Corporation | 4 | $5,081 |
| Beckman Coulter, Inc. | 1 | $4,550 |
| Immunitybio, Inc. | 1 | $2,500 |
| Boehringer Ingelheim | 3 | $2,348 |
| Taiho Oncology, Inc. | 1 | $2,340 |
| Novartis | 1 | $2,025 |
| Bayer | 1 | $1,964 |
| F. Hoffmann-la Roche AG | 1 | $1,900 |
| Regeneron | 4 | $1,759 |
| Bristol Myers Squibb | 1 | $1,625 |
| Illumina, Inc. | 1 | $1,563 |
| Regeneron Healthcare Solutions, Inc. | 2 | $1,343 |
| Astrazeneca UK Limited | 4 | $978 |
| Puma Biotechnology, Inc. | 1 | $917 |
| Array Biopharma Inc | 1 | $103 |
| Tempus AI, Inc | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LORBRENA$33,569
- ALUNBRIG$33,439
- DATROWAY$22,028
- TAGRISSO$18,720
- Trodelvy$15,323
- LUMAKRAS$11,349
- FOUNDATIONONE CDX$10,780
- TECENTRIQ$8,969
- Enhertu$7,982
- RYBREVANT$7,373
- IMFINZI$7,192
- FOUNDATIONFOCUS$6,745
- FOUNDATIONONE HEME$6,745
- FOUNDATIONONE$6,745
- ZEPZELCA$6,592
- EXKIVITY$5,920
- FOUNDATIONACT$4,000
- GENEXPERT$3,000
- LIBTAYO$2,911
- Tepmetko$2,910
How this compares
$362,489 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AlecensaAlectinib Hcl | 12 | $226,913 |
| TagrissoOsimertinib Mesylate | 13 | $219,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Alecensa | $8,500 | $226,91312 claims |
| AstraZenecaTagrisso | $43,616 | $219,13613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 379 medical oncology providers in California.
Other medical oncology in Duarte
- Daneng LiDuarte$467K
- Howard WestDuarte$426K
- Marwan FakihDuarte$203K
- Erminia MassarelliDuarte$176K
- Ravi SalgiaDuarte$142K
- Tanya DorffDuarte$136K
- Karen ReckampDuarte$132K
- Cy SteinDuarte$122K
- Joseph ChaoDuarte$110K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.